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Cancer is a multifaceted disease characterized by heterogeneous genetic alterations and
cellular metabolism, at the organ, tissue, and cellular level. Key features of cancer hetero-
geneity are summarized by 10 acquired capabilities, which govern malignant transformation
and progression of invasive tumors. The relative contribution of these hallmark features to
the disease process varies between cancers. At the DNA and cellular level, germ-line
and somatic gene mutations are found across all cancer types, causing abnormal pro-
tein production, cell behavior, and growth. The tumor microenvironment and its individual
components (immune cells, fibroblasts, collagen, and blood vessels) can also facilitate or
restrict tumor growth and metastasis. Oncology research is currently in the midst of a
tremendous surge of comprehension of these disease mechanisms.This will lead not only
to novel drug targets but also to new challenges in drug discovery. Integrated, multi-omic,
multiplexed technologies are essential tools in the quest to understand all of the various
cellular changes involved in tumorigenesis.This review examines features of cancer hetero-
geneity and discusses how multiplexed technologies can facilitate a more comprehensive
understanding of these features.
Keywords: cancer, heterogeneity, tumormicroenvironment,multiplexing, tumormechanisms,multi-omic analysis,
next-generation sequencing
INTRODUCTION
Cancer can be seen as the summation of many different cell types
and is best described by the hallmarks of cancer (1, 2). To date, 10
hallmarks have been described: self-sufficiency in growth signals;
insensitivity to antigrowth signal; tissue invasion and metastasis;
unlimited proliferation potential; sustained angiogenesis; evad-
ing apoptosis; deregulated metabolism; genomic instability; tumor
promoting inflammation; and avoiding immune destruction (1,
2). These acquired capabilities may vary across individuals, organ
systems, subtypes within an organ, and cancer stage.
The hallmarks of cancer are driven by acquired intra- and
intertumoral genetic and epigenetic variations. Intertumoral het-
erogeneity has resulted in the classification of discrete tumor
subtypes, which are characterized by distinct molecular genetic
profiles, morphology, and expression of specific markers. Intratu-
moral heterogeneity manifests as variations within the tumors,
including cells adopting a range of functional properties and
different biomarker expression patterns. The tumor microenvi-
ronment and its related cell types also contribute to malignant
transformation. Figure 1 illustrates the cellular milieu and inter-
actions within the tumor and surrounding microenvironment,
including immune-cell interplay. This will be further discussed
later in the review. Furthermore, the hereditary genetic baseline
of each individual can modify overall physiology, drug uptake,
metabolism, and half-life/clearance leading to outcome variations.
Similarly, differences in the innate and adaptive immunity and
DNA damage responses play critical roles. The combination of
all of these factors results in a highly complex and multifaceted
disease state.
Understanding the interplay between the different elements
and their roles in tumor progression and treatment response is
a challenging, but important, consideration. It is of particular rel-
evance when developing novel drugs, in understanding how drug
resistance develops, and when directing patients toward effective
secondary therapies. The growing appreciation of cancer com-
plexity has been accompanied by the recognition that tools and
technologies used historically in drug discovery and cancer diag-
nosis are limited in their ability to fully elucidate mechanisms
and pathways at single cell, multicellular, and system level. Conse-
quently, the field is transitioning toward platforms that encompass
multiplexed, multi-omic, and computational technologies. This
review discusses cellular heterogeneity within tumors and consid-
ers how novel technologies are providing new approaches to cancer
research and biomarker identification. Heterogeneity at the level
of cancer progression and tumor evolution is considered first, fol-
lowed by a discussion on the observed diversity at the histological
and molecular level. The focus then switches to the differences in
cell signaling and the importance of the tumor microenvironment
in tumorigenesis. In parallel, examples of current and emerging
methods and technologies that are being used in cancer research
and diagnosis are also highlighted and discussed.
HETEROGENEITY IN CLONAL EVOLUTION DURING TUMOR
PROGRESSION
Cancer arises as a consequence of genetic mutations (3) and epige-
netic alterations (4) within developing neoplastic cells. Currently,
there are two theories that describe the establishment and main-
tenance of tumors: clonal evolution and the stem cell hypothesis.
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FIGURE 1 | Cellular heterogeneity in the tumor and
microenvironment. Most solid tumors grow in a complex
micro-environment consisting of stromal cells, vasculature, infiltrating
immune cells, and complex extracellular matrix (ECM) components. Cell
types and ECM components are identified in the legend. The upper left
panel depicts many elements reported in association with tumor promoting
micreoenvironments. This environment exhibits tumor promoting
characteristics including (1) paracrine signaling axes between tumor cells,
stromal cells, vascular cells and immune cells, (2) neoangiogeneis with
porous/leaky vascular ECM, (3) reactive stroma, (4) ECM remodeling, and
(5) tumor cell invasion and intravasation. Notable tumor promoting
immune-cell phenotypes are highlighted. Many of these factors have been
demonstrated to contribute to invasive growth and metastatic
dissemination of cancer cells. The upper right panel illustrates tumor
micro-environment characteristics reported to be associated with a more
indolent phenotype. Several important characteristics of indolent tumors
including (1) innate immune-cell mediated tumor cell killing, (2) cellular and
humoral adaptive immune-cell anti-tumor responses, (3) normal vasculature
with pericyte coverage and intact basement membrane, (4) quiescent
stroma, and (5) parallel collagen orientation are shown.
The clonal evolution model is based on the premise that over
time, cancers continue to evolve by virtue of a Darwinian process
of genetic drift and natural selection. Genetic instability within the
tumor cell population leads to accumulation of additional muta-
tions within single cells. Thus, a number of genetically divergent
clonal subpopulations exist, with the most aggressive cells driving
tumor progression (3, 5–9).
The stem cell hypothesis suggests that only a subset of can-
cer cells, defined as cancer stem cells, can participate in “clonal”
evolution (10–13) and drive tumor progression, while the other
cells are“evolutionary dead ends”(12, 13). The resulting hierarchi-
cal organization consists of stem cells, intermediate progenitors,
and terminally differentiated progeny. Cells arising from different
cell types will produce tumors of vastly different phenotypes and
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biology (14, 15). This has been demonstrated in several inducible
colon tumor models in which the tumor-suppressing APC pro-
tein was selectively ablated in either an active (LGR5) or quiescent
(Lrig1) stem cell population in the gut. When tumorigenesis was
activated in the LGR5 population, localization of tumors was
restricted to the upper gastrointestinal tract (16) while those orig-
inating from the Lrig1 population developed in the distal colon
(17). The underlying mechanisms for this localized tumorigenesis
remain enigmatic as both stem cell types are found in the crypts
throughout the gastrointestinal tract. Furthermore, evidence from
cancer cell transplantation experiments have established that dif-
ferent malignancies exhibit a broad spectrum of stem cell fre-
quencies [reviewed by Visvader and Lindeman (18)] and different
tumors vary in their cancer stem cell composition (13).
Cancer stem cells have aroused interest as therapeutic targets
because of their purported role in tumorigenesis and metastasis
(10, 19–21) and contribution to chemoresistance (22–24). In vitro
assays have demonstrated that there are distinct populations of
tumorigenic and non-tumorigenic cells in various cancers, includ-
ing breast and colorectal (25, 26), and studies in transgenic models
have shown that tumors arising from stem cells establish more
readily and are more aggressive (27–29). Cancer stem cells may
also contribute to drug resistance and disease recurrence through
expression of multidrug resistance proteins, including ABCB1,
ABCG2, and ABCB5 (30).
While proteomics and genomics methods have been widely
used to elucidate stem cell biology, identification of cancer stem
cells in situ using immunofluorescence methods allows direct
assessment of heterogeneity, cell types, and numbers. Typically,
a number of cell-specific protein markers are needed for such
cell characterization. Some markers, such as ALDH1, CD133, and
CD44, are common across all tumors, while others may be rel-
atively tumor specific, e.g., CD271 in melanoma and Trop2 for
prostate (30). Even within the same cancer type, the cell markers
vary depending upon the different histologic/molecular subtype.
For example, in non-small cell lung cancer (NSCLC), variations in
the expression of stem cell markers have been observed between
adenocarcinoma and squamous cell cancers using multiplexed
immunofluorescence, with similar complexity seen in either of the
two tumor subtypes (representative example shown in Figure 2).
The significance of such stem cell diversity in terms of patient out-
come or drug response remains to be determined. In a recent study
where multiple markers were examined in breast cancer cell lines
and primary tumors, little concordance was seen in co-expression
FIGURE 2 | A representation of heterogeneity in cancer stem cell
marker expression. A series of lung cancers were examined for the
expression of various reported cancer stem cell markers using a
multiplexed protocol on the MultiOmyx™ platform to illustrate the
heterogeneity in cancer stem cell protein markers. Examples of
adenocarcinoma (A,B) show two different cellular profiles with the sample
on the left (A) displaying intratumoral heterogeneity for ALDH1 and CD166
(compare left and right sides), whereas another sample (B) was
homogenous for two of the markers), and devoid of BMI1, LGR5, and
EphB2. Different profiles were found in squamous carcinoma samples
(C,D) with CD44v6 (gray/white) expression found in both samples, and on
the right (D) was accompanied by CDCP1. ALDH1 was only found in a
minor population of tumor cells in both samples, and on the left (C) was
uniquely associated with CD166 minor (arrow) clusters of cells.
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of the markers with clinical responses (31). Conversely, in another
study where three breast stem cell markers (CD24, CD44, and
ALDH1) were examined, expression patterns were found to cor-
relate to histopathological subtype of the tumors (32). Moreover,
tumor subtype has been shown to influence the local stem cell
populations in adjacent normal epithelia in breast cancer, where
triple-negative tumors contained CD44+CD49f+CD133/2+ stem
cells in nine out of nine samples, while in estrogen receptor (ER)-
positive tumors, this was detected in only 7 out of 52 samples
examined (33).
HISTOLOGICAL AND MOLECULAR HETEROGENEITY
Histological assessment is the most common means of distin-
guishing cancer from benign tissues and identifying the subtype.
Molecular subtyping characterizes an additional layer of hetero-
geneity by establishing the predominant genomic and protein
signatures present. This is often found to be complementary to
traditional histological classification, wherein a single histologi-
cal type may be divided into discreet molecular subtypes. Breast
and lung subtypes have been studied extensively, and there is an
emerging understanding of colorectal cancer subtypes. In addi-
tion, it has been suggested that other cancers, such as gastric (34),
prostate (35), and ovarian (36), may also exhibit different molecu-
lar subtypes. As will be elaborated on below, the need for multiple
markers to distinguish histologic and molecular subtypes is cur-
rently enabled by singleplex immunohistochemistry (IHC) and
multiplexed gene-expression assays. These examples represent just
a brief summary of the biological complexity and range of diag-
nostic testing for three major cancer types. The transition from
research biomarker to prognostic or predictive diagnostic test can
involve years of research, biomarker down-selection, verification,
and clinical validation. Successful translation is highly dependent
on a number of key variables including sample collection, quality,
technical performance of the analytical platform, and validation in
adequately powered, clinically relevant patient populations (37).
BREAST CANCER
Five intrinsic molecular subtypes have been identified for breast
cancer: luminal A, luminal B, human epidermal growth fac-
tor receptor 2 (EGFR2 or HER2)-positive, triple-negative, and
normal-like (38). The subtypes partially reflect clinical phenotypes
based on the presence or absence of the ER, progesterone recep-
tor (PgR), and HER2 (39) and each is associated with a distinct
prognosis and clinical outcome. In addition to providing classifi-
cation information, both the ER and the PgR expression (typically
determined by IHC) are valid prognostic and predictive markers
in the adjuvant and metastatic settings. ER is a predictor of a pos-
itive response to endocrine therapy, although not all patients with
ER-positive disease benefit from endocrine therapy, and guidelines
recommend that tumor PgR status is also evaluated (40). Patients
with a positive status for either or both of the receptors typically
receive endocrine therapy (41). HER2 overexpression, as deter-
mined by IHC and/or FISH amplification is generally associated
with poorer prognosis and is also used as a predictive marker for
trastuzumab/HER2-directed therapy (42). Patients negative for
all three markers are referred to as having triple-negative breast
cancer (TNBC). More recently, additional TNBC subtypes have
been described including the“molecular apocrine”group, which is
related to activation of the androgen receptor (43), the“interferon”
subtype (44), and the “claudin-low” subgroup (45). Neoadjuvant
or adjuvant chemotherapy regimens are standard of care for TNBC
patients but as yet there are no approved predictive biomarkers of
therapy response.
The proliferative marker Ki67 may also be useful as a prognostic
indicator for breast cancer patients (46). Ki67 expression by IHC
has been shown to correlate with overall survival and disease-free
survival, with high levels of Ki67 indicative of an increased risk of
recurrence (47). However, controversy remains over the criteria for
defining tumor positivity. Moreover, clinical utility has been ham-
pered by preanalytical, analytical, and scoring variability, although
recent efforts have been made to address this (48).
In addition to standard of care testing for ER, PgR, and HER2,
there are several multimarker tests now available for breast can-
cer outcome including: MammaPrint® (49) (Agendia, Irvine, CA,
USA); a five-antibody IHC panel Mammostrat® (50) (Clarient
Diagnostic Services Inc., Aliso Viejo, CA, USA); Oncotype Dx®
(51) (Genomic Health, Redwood City, CA, USA); the PAM50-
based Prosigna™ assay (52) (NanoString Technologies, Seattle,
WA, USA). Each of these has proven clinical utility for predict-
ing recurrence in patients with ER-positive, node-negative breast
cancer. Oncotype Dx has also been shown to predict chemother-
apy benefit in the high-risk patient group, with minimal benefit
in the low-risk group (53). Consequently, based on the risk of
recurrence score, the test helps physicians determine who is likely
to benefit from adjuvant systemic chemotherapy. Clinical stud-
ies have shown that over 30% of treatment recommendations
changed based on the patient risk score, and this has led to a
net reduction in chemotherapy use (54). As more therapies and
companion diagnostic biomarkers become validated, the need for
multiple gene and protein biomarkers is likely to increase.
LUNG CANCER
Lung cancer is also comprised of two major subtypes: small cell
lung cancer (SCLC) and NSCLC. NSCLC can be divided histo-
logically into adenocarcinoma, squamous cell, and large cell lung
carcinoma (55). The clinical significance of accurate subtyping
is demonstrated with bevacizumab, which is contraindicated in
patients with squamous cell NSCLC (56) due to the elevated risk
of life-threatening hemorrhage (57). Indeed, commercial tests are
now available to distinguish between adenocarcinoma and squa-
mous cell NSCLC. Examples include the ProOnc Squamous Dx
(Prometheus Laboratories Inc., San Diego, CA, USA) based on
quantitative expression of micro RNA miR-205 (58), and the
Pulmotype® test (Clarient Diagnostic Services Inc.), which uses
a panel of five IHC markers (cytokeratin 5/6, MUC-1, TRIM-
29, CEACAM-5, SLC7A5) to aid in distinguishing subtypes (59).
InCyte Diagnostics (Spokane Valley, WA, USA) also offers a panel
of IHC markers including thyroid transcription factor-1 (TTF-1),
napsin A, cytokeratin 5, cytokeratin 7, and p63; a positive stain
for TTF-1 and napsin A supports a diagnosis of adenocarcinoma,
while the others indicate tumors of a squamous subtype.
Non-small cell lung cancer can also be defined by different
molecular subtypes based on mutations within driver oncogenes.
The three most established biomarkers are EGFR mutations,
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echinoderm microtubule-associated protein-like 4 (EML4)-
anaplastic lymphoma kinase (ALK) rearrangements, and KRAS
mutations. Each has been shown to have prognostic and predictive
value. For example, patients whose lung tumors harborEGFR exon
19 deletions or exon 21 (L858R) substitutions are now offered one
of two tyrosine kinase inhibitors, erlotinib or afatinib, as a first-line
treatment (39). However, in those patients with the EML4-ALK
fusion gene [found in 2–7% of NSCLC patients (60)] crizotinib
is the primary first-line treatment option (61). Routine testing for
both EGFR mutations and ALK fusions is now recommended by
the College of American Pathologists and the International Asso-
ciation for the Study of Lung Cancer (62). Other biomarkers are
also being studied for potential utility in guiding NSCLC treat-
ment decisions. These include PIK3CA, HER2, BRAF, ROS, RET,
NRAS, MET, and MEK1. The onerous demands of molecular and
protein analysis on biopsied tumor material may limit the number
of tests that can be conducted.
COLORECTAL CANCER
Colorectal cancer has also been shown to comprise clinically
distinct molecular subtypes, although the exact number is cur-
rently unclear. A recent study (63) defined six clinically relevant
subtypes, each of which is similar to normal colon crypt cells
but with varying degrees of stemness and Wnt signaling. Other
reports have identified three subtypes based on genomic char-
acteristics: the chromosomal-unstable, the microsatellite-unstable
CpG island methylator phenotype (64), and a third subtype, which
is largely microsatellite and chromosomally stable (65). Roepman
et al. (66) also identified and validated three colorectal cancer sub-
types: mismatch repair deficient epithelial, proliferative epithelial,
and mesenchymal; with each subtype potentially having a different
therapy response. In addition to these findings, a recent proteomics
analysis has further refined colorectal cancer classification. The
proteomes of 90 patient samples characterized previously by the
Cancer Genome Atlas were analyzed by mass spectrometry (MS),
and five subtypes were proposed based on consensus cluster analy-
sis (67). Aside from analyzing correlations between genomic and
proteomic features, the authors examined classification agreement
between three genomics-based classifiers and the proteomic sub-
types. Despite some overall consistency, the classifiers exhibited
considerable differences in assigning patients to subtypes. This
suggests that further analyses and categorization approaches may
yield better disease classification.
Other biomarkers used to help treatment decisions in colorec-
tal cancer include the use of KRAS mutation status as a predictive
marker (68) and the use of BRAF mutations as a strong negative
prognostic indicator in KRAS wild-type colorectal cancer (69).
CELL SIGNALING AND HETEROGENEITY
Understanding cellular and molecular differences within cancer
subtypes is critical for understanding disease heterogeneity (70).
With that, there has been a drive to develop and adopt new tech-
nologies capable of single-cell analysis and measurement of acti-
vated pathways and other genomic aberrations. MultiOmyx™(GE
Healthcare, Aliso Viejo, CA, USA) is one such technology that pro-
vides multiplexed protein analysis and DNA alterations (by FISH)
to be imaged and quantified within the same cells of intact single
fixed tissue section (71). Using this technology,a study of formalin-
fixed paraffin-embedded (FFPE) specimens from a cohort of over
700 colorectal cancer patients demonstrated considerable differ-
ences in the phosphorylation of two proteins, ribosomal protein
S6 (S6) and eukaryotic initiation factor 4E binding protein 1
(4E-BP1), in individual cells within tissue microarray tissue cores
(71). Mutually exclusive phosphorylation patterns of these two
canonical substrates of mammalian target of rapamycin complex
1 (mTORC1) were observed in individual cells, in large regions of
most tumors, and in distinct cell lineages (representative images
shown in Figure 3), thus demonstrating differential pathway acti-
vation. Mutual exclusivity of pathway activation was seen in tumor
regions typically consisting of over 2,000 cells, and in cells adja-
cent to one another (Figure 3). Single cell, cluster, and heat map
analyses were used to quantify and visualize the heterogeneity of
the mTOR signaling dynamics in this disease state (71).
Other examples of signaling heterogeneity have been shown
using multispectral imaging of several proteins from a common
signal transduction pathway. For example, multispectral imaging
was used to demonstrate that activation of the c-MET signal-
ing pathway and consequent induction of epithelial–mesenchyme
transition are common features in prostate cancer (72). Another
technology, reverse-phase protein array (RPPA), has been used for
the quantitative analysis of proteins in their phosphorylated or
unphosphorylated forms in arrays of cell lysates, plasma, or serum
samples. Its use in research and clinical settings has recently been
extensively reviewed by Gallagher and Espina (73). The Collabo-
rative Enzyme Enhanced Reactive-immunoassay (CEER) (74) is
another platform that can be used to detect protein expression
and phosphorylation at the single-cell level. By way of example,
CEER has been used to identify heterogeneity in activated signaling
pathways in advanced gastric cancers (75).
In summary, elucidation of the cancer heterogeneity and its
clinical relevance requires multiple approaches, including histo-
logical and subtype analysis, cell composition and distribution,
genomic alterations and in situ, and extracted protein and gene
expression. Depending on the question and desired granularity,
some or all of these technical approaches may be required. The
amount of available sample, its age and state of preservation, and
ability to do potentially complex multi-omic analysis also need to
be considered.
TUMOR MICROENVIRONMENT – HETEROGENEITY AND
ANTICANCER THERAPEUTIC TARGET
Aside from the malignant cells themselves, the tumor microen-
vironment is known to play a vital role in tumorigenesis as its
constituent cells and structures affect how tumor cells grow and
spread (76). The tumor microenvironment is a highly heteroge-
neous mix of cellular and non-cellular components, consisting of
the extracellular matrix (ECM), vasculature, fibroblasts, smooth
muscle cells, immune cells, nerves, and proteins in the immediate
extracellular environment (77). There are at least three distinct
processes through which the tumor micro-environment promotes
tumor growth: stromal cell secretion of paracrine-acting stimu-
latory factors; angiogenesis; and immune-mediated interactions.
These processes are interconnected and work together to produce
a morphological and chemical micro-environment wherein tumor
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FIGURE 3 | A representative image of heterogeneity at the cell
signaling level in colorectal cancer. mTOR targets phospho-Ribosomal
Protein S6 and phospho-4E-BP1 exhibit substantial cellular exclusivity in
colorectal cancer specimens, with rare coexpression (representative of
previously published results (71). This figure shows 20 TMA cores
containing 2,000–5,000 cells, which have been generated to demonstrate
the heterogeneity of cell signaling in colorectal cancer. Rows (A–C) show
different patterns of mutually exclusive p4E-BP1 (red) and pS6 (green)
signals. Many specimens exhibit a strong signal for each phosphorylation
event in exclusive tumor cells (A1–A3). Another notable pattern exhibits
substantial p4E-BP1 expression in tumor cells, and a high level pS6 signal
in stromal cells (A4–C2). In addition, rare tumors exhibit high level signal in
only one of the canonical mTORC1 substrates (C3–C5), or both
simultaneously (D1–D5).
cells thrive due to the ready supply of growth factors, cytokines,
and vasculature (78). Conversely, some tumors are characterized
by a tumor antagonistic microenvironment. Both scenarios are
illustrated in Figure 1. Ongoing efforts to characterize the cells
and tissues of the tumor microenvironment is expected to reveal
additional insights into the mechanisms of tumor progression
and metastasis. These gains should ultimately influence cancer
diagnosis and therapy.
EXTRACELLULAR MATRIX
The ECM is an important component of the microenvironment
and serves as the substrate for cell adhesion and in local growth
factor regulation. The architecture of the ECM is altered dur-
ing carcinogenesis, and its remodeling is believed to be crucial
for tumor malignancy and metastatic progression (79, 80). For
example, in normal breast tissue, collagen I fibrils are relaxed, and
non-oriented. However, in breast cancer, collagen I is often highly
linearized and oriented next to the epithelium or projecting per-
pendicularly into the tissues (Figure 1) (81). Moreover, breast
cancer growth can be selectively accelerated or slowed by increas-
ing or decreasing ECM crosslinking, and progression is accompa-
nied by ongoing increases in ECM stiffness (81). The ECM also
has a key role in disease progression in pancreatic cancer, where
the abundance of ECM induces an abnormal configuration of
blood and lymphatic vessels. The rigidity of the ECM compresses
blood vessels leading to reduced perfusion, which is proposed to
impede the delivery of drugs to neoplastic cells and contribute
to drug resistance (82). Recent in vitro and in vivo mechanistic
studies have pointed to a tripartite cellular interaction with the
ECM, whereby tumor cells and macrophages migrate to endothe-
lial cells by trafficking along collagen fibrils with specific structural
properties (83). These observations underscore the complexities of
cooperativity between cells and associated structures in the tumor
microenvironment.
ANGIOGENESIS
Angiogenesis has long been recognized as playing an important
role in tumor formation. During tumorigenesis, the appropriate
balance between proangiogenic and antiangiogenic molecules and
autocrine and paracrine growth factor stimulation is lost (84).
The main mechanism, known as endothelial sprouting, depends
on vascular endothelial growth factor upregulation and the devel-
opment of functional interactions between endothelial cells, per-
icytes, stromal cells, and the associated ECM (Figure 1) (85, 86).
As angiogenesis is critical for tumor survival, it is a natural and
now well-established target for therapeutic intervention. Modest
improvements in survival are seen on inhibiting angiogenesis in
some cancers suggesting that additional angiogenesis-promoting
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targets alone, or in combination with other targeted therapies, may
yield improved response rates (87, 88).
IMMUNE CELLS
The tumor microenvironment also contains a variety of immune
cells, which play key roles in the initiation and progression of
cancer (illustrated in Figure 1) (89, 90). Two immune-cell types in
particular have been well characterized within the tumor microen-
vironment: T cells and tumor-associated macrophages (TAMs).
TAMs can be separated into two phenotypes, the cytotoxic M1 phe-
notype (91) and the growth-promoting M2 TAMs that are involved
in promoting tumor progression and are thought to correlate with
poor prognosis in some settings (92). TAMs also modify the ECM
and are involved in tumor recognition and antigen presentation
(93). Moreover, they are important components of angiogenesis,
invasion, and metastasis (94), and together with T helper (Th)-2
(95) and Th17 cells (96) can be involved in tumor promotion,
progression, or metastasis. T cells are another important immune
component of the tumor microenvironment. They can be cate-
gorized into different types, including the CD4+ T lymphocytes,
which are further classified into Th cells (Th1, Th2, Th17), T-
regulatory (Treg) cells, and the CD8+ cytotoxic T cells. Each of
these cell types has an important role in supporting tumorigen-
esis. Tumor-localized CD8+ cytotoxic T cells are associated with
indolent disease, while the presence of Th2, Th17, and Treg polar-
ized CD4+ T lymphocytes are linked to more aggressive disease.
Treg cells also have a key role in tumor immune evasion and angio-
genesis (97, 98), and are negative prognostic indicators of overall
survival in metastatic colon cancer (99). Both tumor-infiltrating
lymphocytes and tumor-associated neutrophils are also of con-
sequence in tumorigenesis. Tumor-infiltrating lymphocytes have
been shown to regulate progression and subsequent metastasis
in melanoma (100, 101), whereas tumor-associated neutrophils
can either act as pro- or anti-tumorigenic depending on their
polarization (102).
Clearly, the host immune system is important in controlling
tumor progression and metastasis, and strategies that focus on
targeting the immune system in cancer are gaining popularity.
For example, monoclonal antibodies directed toward the anti-
cytotoxic T-lymphocyte antigen 4 (CTLA-4), programed death 1
(PD-1), and PD-L1 inhibitory immune receptors causing immune
checkpoint blockade have proven very successful in treating
patients with advanced melanoma, where overall survival was
improved and durable objective responses were observed (103).
Adoptive T-cell immunotherapy strategies have also been success-
ful. Sipuleucel-T is an autologous cellular immunotherapy that
has been approved by the FDA for the treatment of asympto-
matic or minimally symptomatic metastatic castration-resistant
prostate cancer. This agent, which activates T cells causing them to
target and attack prostate cancer cells, offered a survival advan-
tage over standard clinical management (104); Sipuleucel-T is
currently recommended as a first-line treatment in asymptomatic
patients (105). More recent strategies, including one described
by Brentjens et al. (106), which use chimeric antigen receptor T
cells to recognize a predefined target by an antibody-derived bind-
ing domain, have proven successful in leukemia where persistent
complete responses have been observed.
However, immune infiltrates are heterogeneous and differences
in cell types and location need to be considered in any analysis
approach (Figure 4). For example, the number, type, and location
of tumor-infiltrating lymphocytes in primary tumors has been
used to develop an “immunoscore” that has not only prognostic
but also predictive value (107). One limitation of this approach
is that multiple markers may need to be used to determine the
exact immunoprofile of each patient. Enumeration and charac-
terization of immune cells and their associated phenotypes in
the tumor microenvironment using in situ multiplexed, analyt-
ical approaches should have utility in this situation. The Multi-
Omyx™ platform has recently been applied in the diagnosis of
Hodgkin Lymphoma. A single slide multiplexing protocol that
includes measurement of nine biomarkers (CD30, CD15, CD45,
Pax5, CD20, CD79a, OCT2, Bob1, and CD3) was used to diagnose
patients with classical Hodgkin Lymphoma with high sensitivity
and specificity (108).
MOVING TECHNOLOGY FORWARD – WHAT’S NEXT FOR
DELINEATING CANCER MECHANISMS AND IDENTIFYING
DIAGNOSTIC BIOMARKERS?
In addition to the previously discussed technologies, there are a
number of other analytical methods used in cancer research, drug,
and biomarker discovery process. As mentioned earlier, IHC is
routinely used for measurement of protein expression in FFPE
tissue, but chromogenic detection is primarily limited to single
marker analysis with non-linear staining intensity. Since a new
tissue section is required for each analyte, analysis of multiple pro-
teins may be problematic if the tissue or tumor area is limited. In
contrast, fluorescence-based imaging allows multiplexed analysis
of up to seven proteins in a single sample and higher-order multi-
plexing (or hyperplexing) fluorescence imaging methods measure
between 60 and 100 proteins in a single sample (71, 109). DNA
FISH is a cytogenetic assay to determine copy number, gene loss,
mutations, or rearrangements, and is commonly used in research
and cancer diagnostics. MultiOmyx protein multiplexing platform
also incorporates a DNA FISH measurement, thus allowing com-
bined interrogation of genome and protein heterogeneity in a
single sample (71).
Flow cytometry is a mature technology routinely used in
research and in clinical practice for the multiplex analysis of hema-
tological and non-solid tumors. It can simultaneously measure
multiplexed-biomarker information on thousands of cells per sec-
ond, and has been critical for defining different immune-cell
populations. Phospho-flow cytometry has also been used to char-
acterize cell signaling networks by measuring the phosphorylation
patterns of proteins in individual cells (110–112). In addition to
multi-parametric measurements, it has been adapted for sorting
live cells into pure populations for subsequent analysis. Over the
last five decades, flow cytometry capabilities have increased with
the availability of new instruments such as the LSRFortessaTM
X-20 (BD Biosciences, San Jose, CA, USA), which is able to mea-
sure 20 fluorescent channels simultaneously. However, while flow
cytometry can be used for tissue analysis after enzymatic dissoci-
ation, the process itself destroys any spatial aspect of expression
patterns, which somewhat limits the utility of the technique for
research. Additionally, tissue disaggregation methods invariably

























































Gerdes et al. Emerging understanding of multiscale tumor heterogeneity
FIGURE 4 | A representative image of the different cell types in the
microenvironment. A multiplexed protocol on the MultiOmyx™ platform
was used to generate an image that illustrates the differences in immune-cell
infiltration seen in colorectal cancer. (A,B)Tumor cells and stromal cells are
labeled with E-cadherin, vimentin, and nuclear counterstain. (C,D) Smooth
muscle actin positive pericytes and smooth muscle and CD31+ endothelial
cells together with extracellular matrix protein collagen IV identifies a subset
of cells and ECM structure in the adjacent tumor microenvironment.
(E,F) CD20+ and CD79+B lymphocytes, CD3+ and CD3+/CD8+ T-lymphocytes
and CD68+ macrophages are present at high levels in the stroma and
infiltrating the epithelium of the tumor in (E), while sparse immune infiltration
is seen in the tumor in (F).
lead to cell damage and/or incomplete dissociation and may be
limiting in the analysis of rare cell populations. IHC and multi-
plex in situ immunofluorescence techniques, on the other hand,
maintain spatial context and information on each individual cell.
In recent years, use of next-generation sequencing (NGS) tech-
nologies for DNA, RNA, and epigenome analysis has dramatically
risen due to decreased cost and technology access and maturity
(113). While enabling unprecedented level of molecular analysis of
samples there are some technical challenges and potential barriers
to clinical adoption. For example, biopsy samples may provide an
insufficient amount of tumor DNA; identification and validation
of actionable mutations requires large clinical trials and complex
bioinformatics tools (114). Formalin-fixed samples present sev-
eral analytical challenges due to increased DNA fragmentation
and chemical modifications caused by the fixation process (115,
116). Depending on the sample age and the extent of the fixation,
sample quality can vary significantly and this can lead to errors
when identifying mutations. This may be especially problematic
for detecting rare somatic mutations in heterogeneous tumors.
For FFPE samples with a low amount of usable input DNA, the
problem of inadequate sensitivity is coupled with a larger number
of false positives due to C to T transitions. RNA is even less stable
than DNA and, furthermore, the quantity and the quality of the
RNA isolated from FFPE tissues is usually inferior relative to that
obtained from fresh tissue (117). In spite of this, optimized and
standardized sample preparation can allow the retrieval of suffi-
cient mRNA for expression analysis (118). Encouraging reports
have shown good correlation between gene expression from FFPE
specimens and fresh-frozen matched tissues or protein expression
measured by IHC (119, 120).
Mass spectrometry is an increasingly common tool for the mul-
tiplexed analysis of tissues with utility in differentiating cancer
cells from normal tissue, and in novel biomarker discovery. The
method can be used to analyze a wide range of analytes (small drug
metabolites to large proteins) and a wide range of sample types.
New methods for sample preparation, ionization, and mass analy-
sis have enhanced current methods while enabling new ones. These
methods can be broadly categorized into three areas: homoge-
nized samples; label-free mass spectrometry imaging (MSI); and
labeled MSI. The initial use of MS for the analysis of tissue that
also attains the highest degree of multiplexing is achieved through
homogenizing the sample and analyzing it with the combination
of liquid chromatography separations and tandem MS detection.
This method has the capability of analyzing and quantifying thou-
sands of analytes, including proteins, metabolites (121, 122), and
lipids (123) from a single sample. For example, Wisniewski et al.
analyzed the proteome of FFPE samples from colonic adenomas
and identified more than 7500 proteins to relate their expres-
sion levels to disease state (124). Variations of the achieved mass
signatures can be used for analysis of post-translational modifica-
tions and quantitation. The ability of this method to discriminate
between many analytes present simultaneously, with varying post-
translational modifications, and at different concentrations, makes
this method most adept for biomarker discovery. The breadth
of this capability does come at a cost; increased time is needed
for sample preparation, protocol development, and data analysis.
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Additionally, spatial information for each analyte is also lost via
homogenation.
Label-free MSI is emerging as an important tool for molecular
profiling of intact tissue samples while preserving spatial informa-
tion about their expression (125). Label-free MSI does not require
prior knowledge of markers to be profiled and is able to readily
differentiate post-translational modifications as well as different
isoforms of proteins. Additionally, the technique is applicable to
multiple target types including drugs, metabolites, lipids, peptides,
proteins, and even nucleic acids. While an MSI method is generally
optimized for one type of target (e.g., lipids), it has the potential to
detect multiple species of that target simultaneously. One limita-
tion of label-free MSI is that it can generally only be used for rela-
tive, not absolute, quantitation, and it produces large data sets that,
depending upon the size of the data set, take weeks to analyze (125).
Labeled-MSI uses antibodies similar to traditional IHC for
detecting specific proteins or molecules in a sample. In labeled-
MSI, the antibodies are labeled with a metal isotope tag that can
be detected by MS. One of the original versions of this, cytom-
etry time-of-flight (CyTOF) MS, combined inductively coupled
plasma with TOF MS and has now been optimized for the real-
time detection of multiple biomarkers in single-cells present in
suspension (126). Recently, this methodology has been extended
to intact tissues, with a new technique known as “imaging mass
cytometry.”Imaging mass cytometry combines high lateral resolu-
tion laser ablation (127) with CyTOF mass cytometry detection to
obtain subcellular spatial information about multiple biomarkers
on FFPE tissue sections (128). The method has resulted in images
with the lateral resolution necessary for morphological assessment
in cancer diagnostics and has the capacity to analyze over 100 bio-
markers simultaneously. It is currently limited by the availability of
metal-tagged antibodies; only 32 rare earth metals are available for
antibody labeling (128). This method was improved upon to cre-
ate multiplexed ion beam imaging (MIBI) where the metal-tagged
antibodies are ionized by the higher spatial resolution method of
Secondary Ion Mass Spectrometry (SIMS) (129). During MIBI
analysis, the metal antibodies are liberated as secondary ions,
which are then analyzed with a magnetic sector mass analyzer;
other mass analyzers (such as TOF) could also be used. This tech-
nique has been used successfully in imaging breast tumors, where
10 different targets were analyzed simultaneously (129).
SUMMARY
As the insights into cancer biology have evolved, emphasis
has shifted toward understanding cancer subtype, cell-to-cell
interactions, signaling pathways, tumor microenvironment, and
immune-mediated responses. A detailed mechanistic understand-
ing of how individual mutations contribute to modifying gene
expression and protein function is required, as is the elucidation of
how the various regulatory and metabolic pathways interconnect.
Novel multi-omic technologies, including those that are based on
multiplexed imaging of intact tissue, NGS, MS analysis, and gene
expression allow the collation of large amounts of information
within cells and tissue, and highlight the mounting challenge of
how to integrate and compare such data. Multi-omic analysis at
the cell level provides a much deeper insight into cell changes,
interactions, and progression to metastatic disease. The use of
quantitative imaging technologies is essential for visualization of
tumor and cell behavior, low abundance proteins, rare cell events,
and spatial distribution of cells and proteins. Adopting a com-
prehensive multi-omic approach should ultimately facilitate the
identification of biomarkers that have diagnostic and prognostic
value, and help match patients to the most appropriate treatment
strategy.
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